Ahead of the Bell: J&J 3Q profit seen higher NEW YORK - Johnson & Johnson, the world's most diverse maker of health care products, is 'a good defensive 'safe-haven' in this time of broader market volatility,' RBC Capital Markets analyst Ryan Bachman recently wrote in a note...
Johnson & Johnson expected to report increase in third - quarter earnings NEW YORK (AP) - Johnson & Johnson, the world's most diverse maker of health care products, is 'a good defensive 'safe-haven' in this time of broader market volatility,' RBC Capital Markets analyst Ryan Bachman recently wrote in...
Ahead of the Bell: J&J 3Q profit seen higher NEW YORK (AP) -- Johnson & Johnson, the world's most diverse maker of health care products, is 'a good defensive 'safe-haven' in this time of broader market volatility,' RBC Capital Markets analyst Ryan Bachman recently wrote in a...
2nd UPDATE: Abbott: Analysis Shows Added Xience Benefits An analysis of combined data from two studies on Abbott Laboratories' (ABT) Xience drug-coated stent shows additional ways in which the heart device outperformed a longtime, top-selling device from Boston Scientific Corp.(BSX), according...
2nd UPDATE: Abbott: Analysis Shows Added Xience Benefits (Adds details on Boston Scientific stents used in studies in paragraphs 15- 16.) Of DOW JONES NEWSWIRES An analysis of combined data from two studies on Abbott Laboratories' (ABT) Xience drug-coated stent shows additional ways in which the...
UPDATE: Abbott: Analysis Shows Added Xience Stent Benefits An analysis of combined data from two studies on Abbott Laboratories' (ABT) Xience drug-coated stent shows additional ways in which the heart device outperformed a longtime, top-selling device from Boston Scientific Corp.(BSX), according...
UPDATE: Abbott: Analysis Shows Added Xience Stent Benefits (Adds details from new analysis in eighth paragraph, details from bioabsorbable stent program in third paragraph, executive comments in 16th paragraph and updated share prices.) Of DOW JONES NEWSWIRES An analysis of combined data from two...
Abbott: Analysis Shows Added Xience Stent Benefits An analysis of combined data from two studies on Abbott Laboratories' (ABT) Xience drug-coated stent shows additional ways in which the heart device outperformed a long-time, top-selling device from Boston Scientific Corp.(BSX), according...
Abbott: Analysis Shows Added Xience Stent Benefits An analysis of combined data from two studies on Abbott Laboratories' (ABT) Xience drug-coated stent shows additional ways in which the heart device outperformed a long-time, top-selling device from Boston Scientific Corp.(BSX), according...
RBC Capital Markets Changes EPS Estimate of SCIELE PHARMA INC: Current Recommendation is Dropped Company: SCIELE PHARMA INC Report Headline: 'Sayonara, Sciele--Discontinuing Coverage' Report Date: October 09, 2008 Current FY EPS Estimate [FY2008]: N/A Previous EPS Estimate for Current FY [FY2008]: 1.81 Current Quarter EPS Estimate [Q4]:...
Biz: Filings disclose solid numbers at Cornerstone The Cary company, which makes allergy and pain medications, is privately held.But as part of its agreement to buy Critical Therapeutics, a publicly traded Massachusetts company, Cornerstone must file securities documents with lots of...
Boston Scientific, Abbott stents tie in study NEW YORK - Abbott Laboratories' Xience and Taxus Liberte, the newest entrants in the $1.9 billion US market for heart stents, dueled to a tie in a study of heart attack victims.The two stents were 'equally efficient' over six months,...
UDPATE: Asian Shares Rise; Govt Moves Provide Some Assurance SINGAPORE (Dow Jones)--Asian share markets are gaining Monday with some comfort from signs world leaders are acting in a more aggressive and coordinated fashion to shore up financial markets and the banking sector.Australia's S&P...
Bank of America settles securities investigations THE REGION Bank of America Corp.agreed to settle investigations into its auction-rate securities sales with the Securities and Exchange Commission, New York Attorney General Andrew M.
Cuomo, and other state regulators.
The deal...
RBC Capital Markets Changes EPS Estimate of ANGIOTECH PHARMACEUTICALS INC: Current Recommendation is Sector Pe Company: ANGIOTECH PHARMACEUTICALS INC Report Headline: 'Reducing Recommendation on Funding Risk' Report Date: October 06, 2008 Current FY EPS Estimate [FY2008]: -0.18 Previous EPS Estimate for Current FY [FY2008]: -0.17 Current Quarter EPS...
RBC Capital Markets Downgrades ANGIOTECH PHARMACEUTICALS INC to SECTOR PERFORM: Current Recommendation is Sect Report Headline: 'Reducing Recommendation on Funding Risk' Current Recommendation: SECTOR PERFORM Previous Recommendation: OUTPERFORM Research Firm: RBC Capital Markets Analyst: DOUGLAS MIEHM Industry: HEALTH/DRUGS RBC Capital...
RBC Capital Markets Changes EPS Estimate of ANGIOTECH PHARMACEUTICALS INC: Current Recommendation is Sector Pe Company: ANGIOTECH PHARMACEUTICALS INC Report Headline: 'Reducing Recommendation on Funding Risk' Report Date: October 06, 2008 Current FY EPS Estimate [FY2008]: -0.18 Previous EPS Estimate for Current FY [FY2008]: -0.17 Current Quarter EPS...
RBC Capital Markets Changes EPS Estimate of ANGIOTECH PHARMACEUTICALS INC: Current Recommendation is Sector Pe Company: ANGIOTECH PHARMACEUTICALS INC Report Headline: 'Reducing Recommendation on Funding Risk' Report Date: October 06, 2008 Current FY EPS Estimate [FY2008]: -0.18 Previous EPS Estimate for Current FY [FY2008]: -0.17 Current Quarter EPS...
RBC Capital Markets Downgrades ANGIOTECH PHARMACEUTICALS INC to SECTOR PERFORM: Current Recommendation is Sect Company: ANGIOTECH PHARMACEUTICALS INC Report Date: October 06, 2008 Report Headline: 'Reducing Recommendation on Funding Risk' Current Recommendation: SEC RBC Capital Markets Downgrades ANGIOTECH PHARMACEUTICALS INC to SECTOR PERFORM:...
Genentech Has Mixed Results In Cancer Fight Genentech has been battling cancer, beating one and succumbing to another.Genentech (nyse: DNA - news - people ) and Biogen Idec (nasdaq: BIIB - news - people ) announced that their drug Rituxan was able to slow the progression of...
[external] Genentech Has Mixed Results In Cancer Fight Genentech has been battling cancer, beating one and succumbing to another.Genentech (nyse: DNA - news - people ) and Biogen Idec (nasdaq: BIIB - news - people ) announced that their drug Rituxan was able to slow the progression of...
[external] Good News For Rituxan Rheumatoid arthritis drug Rituxan helps to fight cancer, but now its makers can actually share that with the world.Genentech (nyse: DNA - news - people ) and Biogen Idec (nasdaq: BIIB - news - people ) announced that their drug Rituxan...
Good News For Rituxan Rheumatoid arthritis drug Rituxan helps to fight cancer, but now its makers can actually share that with the world.Genentech (nyse: DNA - news - people ) and Biogen Idec (nasdaq: BIIB - news - people ) announced that their drug Rituxan...
Rbc Cuts Angiotech Pharmaceuticals To Sector Perform From Outperform (Thomson Financial via COMTEX) -- ANPI | Quote | Chart | News | PowerRating -- Chuck Mikolajczak cm COPYRIGHT Copyright Thomson Financial News Limited 2007.All rights reserved.
The copying, republication or redistribution of Thomson...
Jean Coutu Tgt Cut To C$10 From C$12 By RBC PJC.A.T Jean Coutu Tgt Cut To C$10 From C$12 By RBC >PJC.A.T Jean Coutu Tgt Cut To C$10 From C$12 By RBC PJC.A.T.
